CRMD

CorMedix Inc. [CRMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CRMD Stock Summary

Top CRMD Correlated Resources

CRMD


Top 10 Correlated ETFs

CRMD


Top 10 Correlated Stocks

CRMD


In the News

11:17 29 Mar 2024 CRMD

CorMedix (CRMD) Q4 2023 Earnings Call Transcript

CorMedix Inc. (NASDAQ:CRMD ) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financial Officer Erin Mistry - Executive Vice President, Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Dan Ferry - LifeSci Advisors Conference Call Participants Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Lew Sulewski - Truist Securities Serge Belanger - Needham & Co. Operator Good morning ladies and gentlemen, and welcome to the CorMedix Inc. fourth quarter and full year 2023 earnings call. At this time, all lines are in a listen-only mode.

08:30 29 Mar 2024 CRMD

CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

10:11 29 Mar 2024 CRMD

U.S. FDA approves CorMedix's antimicrobial drug

The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said.

09:55 29 Mar 2024 CRMD

CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript

CorMedix Inc. (NASDAQ:CRMD ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - CEO Matt David - EVP and CFO Phoebe Mounts - EVP and General Counsel Conference Call Participants Jason Butler - JMP Securities Leszek Sulewski - Truist Securities Gregory Renza - RBC Capital Markets Operator Good afternoon, and welcome to CorMedix Third Quarter 2023 Earnings Conference Call. Today's call is being recorded.

08:30 29 Mar 2024 CRMD

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

BERKELEY HEIGHTS, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the third quarter ended September 30, 2023, after the market closes on Tuesday, November 14, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.

08:30 29 Mar 2024 CRMD

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023.

12:22 29 Mar 2024 CRMD

Why Shares of CorMedix Are Slumping Thursday

CorMedix's lead therapy is DefenCath. The company is awaiting word from the FDA on the therapy's approval.

09:30 29 Mar 2024 CRMD

Why Is Cormedix (CRMD) Stock Down 23% Today?

Cormedix (NASDAQ: CRMD ) stock is falling hard on Thursday after the company priced a public offering of its shares. That public offering has the company selling 7.5 million shares of CRMD stock at a price of $4 per share.

08:30 29 Mar 2024 CRMD

Cormedix Inc. To Present At The Jefferies Healthcare Conference

BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be presenting and participating in investor meetings at the Jefferies Healthcare Conference being held in New York on June 7 – 9, 2023.

07:27 29 Mar 2024 CRMD

CorMedix Inc. (CRMD) Q1 2023 Earnings Call Transcript

CorMedix Inc. (NASDAQ:CRMD ) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President and General Counsel Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the CorMedix First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

CRMD Financial details

Company Rating
Sell
Market Cap
214.86M
Income
401.56M
Revenue
29.7K
Book val./share
1.47
Cash/share
1.53
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
12 Mar 2024
P/E
0.51
Forward P/E
-18.09
PEG
-0
P/S
6661.89
P/B
2.45
P/C
2.72
P/FCF
-5.82
Quick Ratio
11.29
Current Ratio
11.61
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
9.16
EPS next Y
-0.23
EPS next Q
-0.26
EPS this Y
-1.33%
EPS next Y
-102.51%
EPS next 5Y
-90.17%
EPS last 5Y
-13.29%
Revenue last 5Y
-31.38%
Revenue Q/Q
-
EPS Q/Q
-32%
-
-
-
-
SMA20
16.62%
SMA50
12.93%
SMA100
22.43%
Inst Own
28.49%
Inst Trans
0.7%
ROA
439%
ROE
-207%
ROC
-0.5%
Gross Margin
99%
Oper. Margin
-140321%
Profit Margin
1351973%
Payout
-
Shs Outstand
54.81M
Shs Float
53.71M
-
-
-
-
Target Price
-
52W Range
2.57-6.09
52W High
-30.67%
52W Low
+108%
RSI
66.53
Rel Volume
0.87
Avg Volume
437.49K
Volume
379.83K
Perf Week
9.47%
Perf Month
35.06%
Perf Quarter
21.99%
Perf Half Y
12.74%
-
-
-
-
Beta
1.847
-
-
Volatility
0.13%, 0.29%
Prev Close
1.22%
Price
4.16
Change
0.97%

CRMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.020.010.010.010
Net income per share
-1.51-0.68-0.77-0.75-0.74
Operating cash flow per share
-1.33-0.62-0.77-0.56-0.6
Free cash flow per share
-1.33-0.62-0.77-0.6-0.61
Cash per share
0.991.181.631.741.47
Book value per share
-10.05-8.09-7.61-6.52-6.84
Tangible book value per share
0.280.981.551.671.37
Share holders equity per share
-10.05-8.09-7.61-6.52-6.84
Interest debt per share
0.340.030.040.020.02
Market cap
114.92M175.83M212.22M171.38M169.96M
Enterprise value
103.42M159.3M171.15M118.75M127.39M
P/E ratio
-4.28-10.7-9.63-6.08-5.72
Price to sales ratio
267.38620.71887.07897.582.6K
POCF ratio
-4.85-11.68-9.66-8.1-6.98
PFCF ratio
-4.84-11.65-9.61-7.59-6.92
P/B Ratio
-0.64-0.9-0.98-0.7-0.62
PTB ratio
-0.64-0.9-0.98-0.7-0.62
EV to sales
240.62562.39715.42621.951.95K
Enterprise value over EBITDA
-3.85-7.7-6.31-4.03-4.2
EV to operating cash flow
-4.36-10.58-7.79-5.61-5.23
EV to free cash flow
-4.35-10.56-7.75-5.26-5.18
Earnings yield
-0.23-0.09-0.1-0.16-0.17
Free cash flow yield
-0.21-0.09-0.1-0.13-0.14
Debt to equity
-0.030000
Debt to assets
0.3300.020.010.01
Net debt to EBITDA
0.430.81.521.791.41
Current ratio
2.45.0411.5812.449.44
Interest coverage
-14.34K-26.68-819.26-1.85K-1.15K
Income quality
0.880.9210.750.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
18.790000
Research and developement to revenue
43.7939.0255.9268.78163.28
Intangibles to total assets
00000
Capex to operating cash flow
000.010.070.01
Capex to revenue
-0.11-0.13-0.47-7.46-3.35
Capex to depreciation
-0.66-0.5-0.88-23.03-2.59
Stock based compensation to revenue
2.588.6110.4526.4162.22
Graham number
18.4511.1311.4910.4810.65
ROIC
0.160.080.10.120.11
Return on tangible assets
-1.43-0.56-0.45-0.41-0.48
Graham Net
0.220.951.451.581.29
Working capital
10.9M23.52M44.02M61.12M53.24M
Tangible asset value
4.93M23.65M44.22M62.8M55.06M
Net current asset value
4.77M23.52M43.1M60.32M52.57M
Invested capital
-0.030000
Average receivables
37.53K5.47K1.7K24.36K22.68K
Average payables
2.2M1.81M1.08M1.67M2.21M
Average inventory
511.35K383.49K241.01K73.29K1.5K
Days sales outstanding
9.260.055.1286.730
Days payables outstanding
2.38K1K2.01K5.41K215.26K
Days of inventory on hand
394.19331255.817.370
Receivables turnover
39.428.09K71.264.210
Payables turnover
0.150.360.180.070
Inventory turnover
0.931.11.4349.510
ROE
0.150.080.10.110.11
Capex per share
000-0.04-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.16-0.199.77-0.25-0.17
Operating cash flow per share
-0.15-0.15-0.24-0.19-0.15
Free cash flow per share
-0.15-0.15-0.24-0.19-0.15
Cash per share
1.431.411.271.161.53
Book value per share
1.37-6.58-6.48-6.551.47
Tangible book value per share
1.371.321.221.081.47
Share holders equity per share
1.37-6.58-6.48-6.551.47
Interest debt per share
0.020.020.020.020.01
Market cap
116.55M176.63M182.54M180.1M209.25M
Enterprise value
74.13M134.06M157.81M160.95M156.64M
P/E ratio
-4.32-5.50.11-3.99-5.37
Price to sales ratio
17.1K5.95K000
POCF ratio
-19.44-28.7-17.56-21.01-24.06
PFCF ratio
-19.2-28.11-17.54-20.99-24.03
P/B Ratio
2.07-0.64-0.64-0.612.51
PTB ratio
2.07-0.64-0.64-0.612.51
EV to sales
10.87K4.51K000
Enterprise value over EBITDA
-10.83-16.34-14.32-13.63-16.17
EV to operating cash flow
-12.36-21.78-15.18-18.78-18.01
EV to free cash flow
-12.21-21.33-15.16-18.76-17.99
Earnings yield
-0.06-0.052.36-0.06-0.05
Free cash flow yield
-0.05-0.04-0.06-0.05-0.04
Debt to equity
0.010000.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
6.25.192.241.625.43
Current ratio
11.799.4412.157.3911.61
Interest coverage
-793.29-955.93-1.26K-2.02K-798.24
Income quality
0.870.750.980.760.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
343.1595.72000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.02000
Capex to revenue
-11.21-4.33000
Capex to depreciation
-3.59-5.72-0.88-0.36-0.58
Stock based compensation to revenue
144.2829.43000
Graham number
2.245.3337.756.052.39
ROIC
-0.120.03-1.580.04-0.12
Return on tangible assets
-0.11-0.137.27-0.2-0.11
Graham Net
1.291.241.150.981.39
Working capital
54.6M53.24M52.11M47.24M81.39M
Tangible asset value
56.31M55.06M53.93M49.05M83.2M
Net current asset value
53.9M52.57M51.48M46.64M80.84M
Invested capital
0.010000.01
Average receivables
0.50.5000
Average payables
2.13M1.98M1.82M2.17M2.64M
Average inventory
994.5134.5000
Days sales outstanding
0.010000
Days payables outstanding
108.28K488.16K2.63K5.14K4.14K
Days of inventory on hand
16.480000
Receivables turnover
6.82K0000
Payables turnover
000.030.020.02
Inventory turnover
5.460000
ROE
-0.120.03-1.510.04-0.12
Capex per share
00000

CRMD Frequently Asked Questions

What is CorMedix Inc. stock symbol ?

CorMedix Inc. is a US stock , located in Berkeley heights of Nj and trading under the symbol CRMD

What is CorMedix Inc. stock quote today ?

CorMedix Inc. stock price is $4.16 today.

Is CorMedix Inc. stock public?

Yes, CorMedix Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap